Multiple Myeloma Drug Trial Paused Due to Cases of Nerve Damage
This week on DocWire, Pfizer Inc. paused enrollment in a phase 2 clinical trial for its investigational B cell maturation antigen (BCMA)/CD3-targeted drug for multiple myeloma after three patients in an earlier phase trial of the drug developed peripheral neuropathy, or damage to the peripheral nerves. “We have collected information about the cases, and the formal response package will be submitted to the FDA,” said a Pfizer spokesperson.
FDA Commits to Ban Menthol Cigarettes
In other news, the FDA has committed to ban menthol flavoring in cigarettes and cigars, as well as any flavoring in cigars, the agency announced last week. In their statement, the FDA cited a study projecting that a U.S. ban on menthol would lead to around 633,000 prevented deaths by 2050, including 237,000 deaths averted for African Americans.
Fertility Concerns May Affect Breast Cancer Patients’ Treatment Decisions Over their Cancer Care Journey
For young women with breast cancer, concerns about how certain treatments may affect their fertility might play a significant role in treatment-related decisions, according to a study. One third of women surveyed said fertility concerns affected their decisions surrounding endocrine therapy treatment. Those who had never given birth or had only one child were much more likely than those who had at least two children to say they had concerns about fertility.
Patients with Health Conditions More Likely to be Screened for Colorectal Cancer
Patients with underlying health conditions were more likely to be screened for colorectal cancer than those without other comorbidities, according to a study published in the Journal of Osteopathic Medicine. Patients with diabetes, hypertension, skin cancer, chronic obstructive pulmonary disease (COPD), arthritis, depression, and chronic kidney disease were significantly more likely to be screened than those without these health conditions.